| Prevalence | 10-20% in adults over age 65 |
| Annual progression to dementia | 10-15% of individuals with MCI |
| Stable or reverted | Some individuals remain stable; 17-32% may revert to normal cognition |
| Risk factors | Older age, lower education, cardiovascular disease, diabetes |
| Single-domain aMCI | Memory impairment in isolation |
| Multi-domain aMCI | Memory impairment with additional domain deficits |
| Single-domain naMCI | Impairment in one non-memory domain |
| Multi-domain naMCI | Deficits across multiple non-memory domains |
| A (Amyloid) | Aβ42 in CSF or amyloid PET positivity |
| T (Tau) | Phosphorylated tau (p-tau181, p-tau217) in CSF or tau PET positivity |
| N (Neurodegeneration) | Total tau, neurofilament light chain, MRI volumetric measures, or FDG-PET hypometabolism |
| Amyloid PET | Gold standard for detecting amyloid plaque burden |
| Databases | OMIMOrphanetClinicalTrialsPubMed |
No AI portrait yet
No comments yet. Be the first to comment!